GlassScriptPhysician profile
William P Newman
NPI 1316906837
$5,447.30
in general payments reported to CMS, 2019-2025
32 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,102 · 2021: $13.78 · 2022: $363 · 2023: $881 · 2024: $1,023 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,968.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $852.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $671.40 | 2022-2025 | |
| Glaxosmithkline, LLC. | $656.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $585.93 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $561.53 | 2019-2025 | Jardiance |
| Pfizer INC. | $397.27 | 2019-2025 | |
| Novo Nordisk INC | $258.19 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $240.11 | 2019-2025 | Capvaxive, Gardasil 9 |
| Dexcom, INC. | $191.80 | 2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $162.73 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $126.37 | 2022-2024 | Linzess |
| Janssen Pharmaceuticals, INC | $119.58 | 2019 | |
| Coloplast Corp | $111.03 | 2025 | |
| Amgen INC. | $85.71 | 2019-2023 | Repatha, Otezla |
| Abbott Laboratories | $67.43 | 2022-2024 | Freestyle Libre |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $44.35 | 2019-2022 | |
| Phadia US INC. | $36.68 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $31.88 | 2019-2025 | Zoryve |
| Sanofi Pasteur INC. | $27.59 | 2019 | |
| Sebela Pharmaceuticals INC. | $21.43 | 2019 | |
| Hikma Pharmaceuticals USA | $21.43 | 2019 | |
| Phathom Pharmaceuticals, INC. | $20.28 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $20.18 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $19.44 | 2023 | |
| Idorsia Pharmaceuticals US INC | $17.48 | 2023 | Quviviq |
| Exact Sciences Corporation | $17.17 | 2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $15.16 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.41 | 2025 | Xifaxan |
| Genentech USA, INC. | $14.27 | 2019 | |
| Allergan, INC. | $13.93 | 2019 | |
| Amarin Pharma, INC. | $12.29 | 2019 | |
| Medtronic USA, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.